Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 5/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | QSOX1 | O00391 | 1/20 | 0.65 |
| ▸ | RGS12 | O14924 | 1/20 | 0.65 |
| ▸ | PMM2 | O15305 | 1/20 | 0.65 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.65 |
| ▸ | GMNN | O75496 | 1/20 | 0.65 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | CYBB | P04839 | 1/20 | 0.65 |
| ▸ | BCHE | P06276 | 1/20 | 0.65 |
| ▸ | GLA | P06280 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | G6PD | P11413 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5916641 | 0.89 | METAP2 (0.67) | METAP2KDM4EMEN1QSOX1RGS12 | |
| SCHEMBL5916633 | 0.84 | METAP2 (0.45) | METAP2KDM4EMEN1QSOX1RGS12 | |
| SCHEMBL10745858 | 0.83 | METAP2 (0.64) | METAP2KDM4EMEN1QSOX1RGS12 | |
| SCHEMBL5916961 | 0.83 | ALDH1A1 (0.53) | METAP2KDM4EMEN1QSOX1RGS12 | |
| SCHEMBL10501752 | 0.82 | MEN1 (0.41) | METAP2KDM4EMEN1QSOX1RGS12 | |
| SCHEMBL5916875 | 0.81 | METAP2 (0.67) | METAP2KDM4EMEN1QSOX1RGS12 | |
| SCHEMBL10501663 | 0.81 | METAP2 (0.67) | METAP2KDM4EMEN1QSOX1RGS12 | |
| SCHEMBL5916572 | 0.81 | METAP2 (0.65) | METAP2KDM4EMEN1QSOX1RGS12 | |
| SCHEMBL10501773 | 0.81 | METAP2 (0.70) | METAP2KDM4EMEN1QSOX1RGS12 | |
| SCHEMBL1351720 | 0.80 | METAP2 (0.74) | METAP2KDM4EMEN1QSOX1RGS12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060135569-A1 | Use of benzisoselenazolone compounds against ischemic myocardial damage | INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2006-06-22 | — | — | US | claimed |
| EP-1541145-A1 | THE USE OF BENZISOSELENAZOLONE COMPOUNDS AGAINST ISCHEMIC MYOCARDIAL DAMAGE | Institute of Materia, Chinese Academy of Medical Sciences (CN) | 2005-06-15 | — | — | EP | claimed |
| US-20260000645-A1 | USE OF EBSELEN OR ONE OF THE DERIVATIVES THEREOF TO TREAT MITOCHONDRIAL PATHOLOGIES OR DYSFUNCTIONS | ASS FRANCAISE CONTRE LES MYOPATHIES (FR) | 2026-01-01 | — | — | US | disclosed |
| EP-4551214-A1 | USE OF EBSELEN OR ONE OF THE DERIVATIVES THEREOF TO TREAT MITOCHONDRIAL PATHOLOGIES OR DYSFUNCTIONS | Association Française contre les Myopathies (FR) | 2025-05-14 | — | — | EP | disclosed |
| CN-119768165-A | Use of ebselen or one of its derivatives for the treatment of mitochondrial conditions or dysfunctions | 法国抗肌病协会 | 2025-04-04 | — | — | CN | disclosed |
| WO-2024008788-A1 | USE OF EBSELEN OR ONE OF THE DERIVATIVES THEREOF TO TREAT MITOCHONDRIAL PATHOLOGIES OR DYSFUNCTIONS | ASSOCIATION FRANCAISE CONTRE LES MYOPATHIES (FR) | 2024-01-11 | — | — | WO | disclosed |
| US-20060135569-A1 | Use of benzisoselenazolone compounds against ischemic myocardial damage | INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2006-06-22 | — | — | US | disclosed |
| EP-1541145-A1 | THE USE OF BENZISOSELENAZOLONE COMPOUNDS AGAINST ISCHEMIC MYOCARDIAL DAMAGE | Institute of Materia, Chinese Academy of Medical Sciences (CN) | 2005-06-15 | — | — | EP | disclosed |
| EP-0154851-B1 | BENZISOSELENAZOLETHIONES,PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL PRODUCTS CONTAINING THESE COMPOUNDS | A. Nattermann & Cie. GmbH (DE) | 1989-08-02 | — | — | EP | disclosed |
| US-4711961-A | Benzisoselenazolethiones and process for the treatment of various diseases in humans | A. NATTERMANN & CIE GMBH (DE) | 1987-12-08 | — | — | US | disclosed |
| EP-0154851-A1 | Benzisoselenazolethiones,process for their preparation and pharmaceutical products containing these compounds | A. Nattermann & Cie. GmbH (DE) | 1985-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000645-A1 | USE OF EBSELEN OR ONE OF THE DERIVATIVES THEREOF TO TREAT MITOCHONDRIAL PATHOLOGIES OR DYSFUNCTIONS | ERAL1, MT-CO3, GFM1 | METAP2 1071/4885KDM4E 4164/4885MEN1 1710/4885 |
| US-20060135569-A1 | Use of benzisoselenazolone compounds against ischemic myocardial damage | TNNI3, TNNT2, MYLK2 | METAP2 4321/4885KDM4E 2585/4885MEN1 4647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.